Among the 7 targets prioritized under both the 22Q1 and 23Q2 DepMap releases, there were two genes for targets with FDA‐approved agents that have been tested clinically in non‐malignant diseases but not in cancer (UGCG, P2RY6). This evidence concerns the gene P2RY6 and cancer.